Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genome-wide cell-free DNA fragmentation in patients with cancer

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  • Maria Thomsen
  • Eva Skovlund
  • Halfdan Sorbye
  • Nils Bolstad
  • Kjell Johannes Nustad
  • Bengt Glimelius
  • Per Pfeiffer
  • Elin H Kure
  • Julia S Johansen
  • Kjell Magne Tveit
  • Thoralf Christoffersen
  • Tormod Kyrre Guren
Vis graf over relationer

BACKGROUND: Mutation status of RAS and BRAF, as well as serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9), are biomarkers used in clinical management of patients with gastrointestinal cancers. This study aimed to examine the prognostic role of these biomarkers in a patient population that started first-line chemotherapy for unresectable metastatic colorectal cancer (mCRC) in the NORDIC-VII study.

METHODS: CEA and CA 19-9 were measured in serum samples from 545 patients obtained before the start of chemotherapy. Four hundred and ninety-four patients had detectable levels of carbohydrate antigen 19-9 (CA 19-9). RAS (exons 2-4) and BRAF (V600E) mutation status were available from 440 patients. Overall survival (OS) was estimated in patient groups defined by serum CEA or CA 19-9 levels using cut-off values of 5 µg/L and 35 kU/L, respectively, in the total population and in subgroups according to RAS and BRAF mutation status.

RESULTS: For both CEA and CA 19-9, elevated serum levels were associated with reduced OS in adjusted analyses which included RAS and BRAF mutation status, baseline World Health Organization performance status, and levels of alkaline phosphatase and C-reactive protein. The negative prognostic information provided by an elevated CA 19-9 level was particularly marked in patients with BRAF mutation (hazard ratio = 4.35, interaction P = 0.003, in an adjusted model for OS).

CONCLUSIONS: High baseline serum concentrations of CEA and CA 19-9 provide independent information of impaired prognosis in mCRC. In patients with BRAF-mutant tumours, elevated serum CA 19-9 may identify a subgroup with highly aggressive disease and could contribute to improving therapeutic decisions.

OriginalsprogEngelsk
TidsskriftBritish Journal of Cancer
Vol/bind118
Udgave nummer12
Sider (fra-til)1609-1616
Antal sider8
ISSN0007-0920
DOI
StatusUdgivet - jun. 2018

ID: 56563818